--- a
+++ b/clusters/9knumclustersv2/clust_119.txt
@@ -0,0 +1,90 @@
+Histologically or cytologically confirmed cholangiocarcinoma.
+Histologically or cytologically confirmed prostate cancer
+Patients must have histologically or cytologically confirmed non-rhabdomyosarcoma of soft tissue or bone at any site
+Have histologically or cytologically confirmed SCLC that meets:
+Histologically or cytologically confirmed diagnosis of metastatic medullary thyroid cancer
+Histologically or cytologically confirmed diagnosis of melanoma.
+Histologically or cytologically confirmed SCLC (either limited or extensive disease) or LCNEC, that has relapsed from the most current treatment or was refractory to treatment
+Histologically or cytologically confirmed diagnosis of melanoma
+Histologically or cytologically confirmed limited or extensive disease stage of SCLC. The disease should be progressing during or relapsing after the previous treatment.
+Histologically or cytologically confirmed, treatment-naive esophageal squamous cell carcinoma
+Histologically or cytologically confirmed metastatic UM
+Histologically or cytologically confirmed AML according to the WHO classification
+Histologically or cytologically confirmed diagnosis of prostate cancer
+Histologically or cytologically confirmed diagnosis of advanced disease of any of the following tumor types:
+Patients must have histologically or cytologically confirmed metastatic or recurrent RCC (any histologic subtype)
+Histologically or cytologically confirmed PSCC
+Patients must have must have histologically or cytologically confirmed SCLC
+Histologically or cytologically confirmed hepatocellular carcinoma or biliary tract cancer.
+Histologically or cytologically confirmed diagnosis of early stage prostate cancer
+Histologically or cytologically confirmed BRAFV wild-type melanoma
+Histologically or cytologically confirmed ovarian epithelial cancer
+Histologically or cytologically confirmed prostate carcinoma.
+Histologically or cytologically confirmed hematologic malignancy
+Subjects with histologically or cytologically confirmed extensive stage disease SCLC
+Have histologically or cytologically confirmed diagnosis of pancreatic carcinoma
+Diagnosis of histologically or cytologically confirmed metastatic or non-resectable synovial sarcoma
+CAPMATINIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanoma
+CERITINIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanoma
+REGORAFENIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanoma
+ENTRECTINIB INCLUSION CRITERIA: Histologically or cytologically confirmed invasive melanoma
+Patients must have histologically or cytologically-confirmed diagnosis of progressive or recurrent malignancy as follows:
+Histologically or cytologically documented disease
+Pathologically (histologically or cytologically) confirmed diagnosis of esophageal squamous cell carcinoma (ESCC)
+Histologically or cytologically confirmed
+Histologically or cytologically confirmed (patients with mixed histologies are required to have a dominant transitional cell pattern.)
+Histologically or cytologically confirmed metastatic or recurrent tumor types
+Histologically or cytologically confirmed diagnosis of Ewing sarcoma and have progressed on or after standard therapies.
+Histologically or cytologically confirmed solid tumors or hepatocellular carcinoma with known disease progression.
+Histologically- or cytologically-confirmed mCRC.
+Histologically or cytologically confirmed BRAF- or MEK-mutated melanoma
+Patients with histologically or cytologically confirmed metastatic NETs of any origin of low or intermediate grade (Part )
+In dose escalation, patients must have histologically or cytologically confirmed metastatic disease from any solid tumor; in dose expansion, patients must have histologically or cytologically confirmed metastatic melanoma, renal cell carcinoma, ovarian cancer, or colorectal cancer
+Patients without histologically or cytologically confirmed node metastases or any other metastases
+Patients must have histologically or cytologically confirmed peritoneal surface malignancies from primary appendiceal tumors
+Histologically or cytologically confirmed transitional cell carcinoma of the genitourinary tract
+Histologically or cytologically confirmed carcinoma of the breast
+Have histologically or cytologically confirmed melanoma
+Patients with a histologically or cytologically confirmed diagnosis of breast cancer; patients must have metastatic HER positive (+) disease
+Subject has a definitive histologically or cytologically confirmed diagnosis of HER(-) metastatic breast cancer.
+Histologically or cytologically confirmed melanoma.
+Histologically or cytologically confirmed metastatic breast cancer
+Histologically or cytologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group [VALG] staging system)
+Histologically or cytologically confirmed diagnosis of pancreatic cancer.
+Histologically or cytologically confirmed advanced fibrolamellar carcinoma (FLC).
+Inclusion Criteria:\n\n        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please\n        visit www.BMSStudyConnect.com\n\n          -  Patients with metastatic or advanced solid tumors\n\n          -  Women with histologically or cytologically confirmed triple negative breast carcinoma\n\n          -  Participants with histologically or cytologically confirmed pancreatic adenocarcinoma\n\n          -  Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer\n             (NSCLC)\n\n        Exclusion Criteria:\n\n          -  Active brain metastases or leptomeningeal metastases.\n\n          -  Any serious or uncontrolled medical disorder\n\n          -  Prior malignancy active within the previous  years\n\n        Other protocol defined inclusion/exclusion criteria could apply
+Histologically or cytologically confirmed carcinoma of the breast
+Patients must have histologically or cytologically confirmed evidence of pancreatic carcinoma
+Histologically or cytologically confirmed diagnosis of HCC
+Histologically or cytologically confirmed metastatic PDAC, no more than  prior chemotherapy regimen or treatment-nave patients
+Histologically or cytologically confirmed diagnosis of biliary tract adenocarcinoma/cholangiocarcinoma
+Patients must have histologically or cytologically confirmed gastrointestinal (GI) malignancies or ovarian cancer prior to entering this study
+Histologically or cytologically confirmed carcinoma of the prostate
+Histologically or cytologically confirmed breast cancer with evidence of metastatic disease.
+Histologically or cytologically confirmed diagnosis
+Patients must have histologically or cytologically confirmed diagnosis of cancer not amenable to curative therapy.
+Histologically or cytologically confirmed urothelial carcinoma.
+Patients must have histologically or cytologically confirmed cancer
+Patient has histologically/cytologically-confirmed HNSCC.
+Patients with histologically/cytologically-confirmed HNSCC
+Histologically or cytologically confirmed prostate cancer
+Histologically or cytologically confirmed disease;
+Patient has a histologically and/or cytologically confirmed diagnosis of breast cancer
+Participants must have histologically or cytologically confirmed diagnosis of SCLC
+Subjects with a histologically or cytologically confirmed acute leukemia who are refractory to or have exhausted all available therapies
+Histologically or cytologically documented breast cancer
+Histologically or cytologically confirmed melanoma
+Histologically or cytologically confirmed locally residual or recurrent cancer of the rectum or anus
+Histologically or cytologically confirmed breast carcinoma
+Histologically or cytologically confirmed salivary gland carcinoma.
+Histologically or cytologically confirmed diagnosis of mCRC
+Histologically or cytologically confirmed diagnosis of prostate cancer
+Have histologically or cytologically-confirmed malignant disease in an advanced incurable stage
+Histologically and/or cytologically confirmed diagnosis of ER+/HER- breast cancer
+Histologically or cytologically confirmed, stage I-III breast cancer
+Adult patients >  years with histologically or cytologically confirmed Peripheral T-cell lymphoma (PTCL)
+Men and women,  years or older, with histologically or cytologically-confirmed either:
+Histologically or cytologically confirmed breast cancer
+Have histologically or cytologically confirmed small bowel carcinoid tumor
+Histologically or cytologically confirmed primary breast cancer.
+Age ?  years with histologically- or cytologically-confirmed, extensive-stage, chemotherapy-nave SCLC